EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy

@article{Giammarile2008EANMPG,
  title={EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy},
  author={Francesco Giammarile and Arturo Chiti and Michael Lassmann and Boudewijn Brans and GeorgeB. Flux},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2008},
  volume={35},
  pages={1039-1047}
}
Meta-iodobenzylguanidine, or Iobenguane, is an aralkylguanidine resulting from the combination of the benzyl group of bretylium and the guanidine group of guanethidine (an adrenergic neurone blocker). It is a noradrenaline (norepinephrine) analogue and so-called “false” neurotransmitter. This radiopharmaceutical, labeled with 131I, could be used as a radiotherapeutic metabolic agent in neuroectodermal tumours, that are derived from the primitive neural crest which develops to form the… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Compostos iodados em diagnóstico e em terapêutica

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Is there a benefit of I - 131 - MIBG therapy FOR in the treatment of children with stage 4 neuroblastoma ?

KK Solanki, J Bomanji, +3 authors KE Britton
  • 2006

Is there a benefit of I-131-MIBG therapy FOR in the treatment of children with stage 4 neuroblastoma? Nuklearmedizin 2006;45(4):145–51

M Schmidt, T Simon, +3 authors F Sudbrock
  • 2006
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…